62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials

Abstract

Chemotherapy (CT) followed by endocrine therapy (ET) is the current standard of care for high-risk hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC). The monarchE, with 27-months follow-up, showed that the addition of abemaciclib for 2 years in combination with ET improves the 3-years invasive relapse rate (IRR) and distant relapse rate (DRR) for patients (pts) with high-risk EBC. Obtaining data on the long-term risk of relapse is needed to put into context the magnitude of abemaciclib benefit.